Effects of nasal desmopressin versus cyproheptadine on negative symptoms in patients with schizophrenia

Comparison of the effects and side effects of nasal desmopressin versus cyproheptadine on negative symptoms in patients with schizophrenia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160523028008N33

Enrollment

210

Registered

2025-02-12

Start date

2025-02-10

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: Cyproheptadine at a dose of 4-6 milligrams, three times a day for 8 weeks. Intervention 2: Intervention group: Patients are treated with 10 micrograms per day, equi

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with schizophrenia with negative symptoms

Exclusion criteria

Exclusion criteria: Patient's refusal to participate in the study Accompaniment of illness with physical disorders (cardiovascular incidents, glandular diseases, liver and kidney diseases).

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: At the beginning of the study and at weeks 4 and -8 after the start of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Effatpanah

Hamedan University of Medical Sciences

effatpanahnahzam@yahoo.com+98 912 747 8714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026